Please assess the completion status of the following clinical trial:

Trial Title: Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Patient criteria : Donor Treg infusion (DTI) and control arms.~* Signed informed consent.~* Grafts from HLA-identical siblings or HLA-matched unrelated donor (1 of 10 HLA-mismatch is allowed).~* ≥ 18 years of age.~* Steroid-refractory or steroid-resistant chronic GVHD defined as:~  * development of 1 or more new sites of disease while being treated for chronic GVHD,~ * progression of existing sites of disease while receiving treatment for chronic GVHD,~ * failure to improve despite at least 1 month of standard treatment for chronic GVHD.~or severe chronic GVHD and contra-indication to the use of steroids and at least failed one prior line of treatment.~* Severe chronic GVHD according to NIH definition.~* No prior failure of rapamycine as treatment for chronic GVHD~* No contra-indication to the use of rapamycin.~* No alemtuzumab administration in the last 6 months.~* GFR \> 25 mL/min.~* No HIV seropositivity.~* No fungal infection with radiological progression after treatment with amphotericine B or active azoles for \> 1 month.~* No other uncontrolled infection.~* No progression of the hematological malignancy.~* Karnofsky performance score ≥ 70%.~* DLCO \> 35% and no need of supplemental continuous oxygen.~* No active post-transplant microangiopathy and no previous microangiopathy while on rapamycine.~* No uncontrolled hypertriglyceridemia.~  2 Donor criteria : DTI arm only.~* Donor ≥ 18 years of age.~* Written informed consent to perform apheresis from the donor (all patients) and permission from the third party donor registry (in case of unrelated donor).~* Standard criteria for leukapheresis and DLI following complete work-up according to standard procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donor Treg infusion arm (Type: EXPERIMENTAL): Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
- Control (Type: ACTIVE_COMPARATOR): Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).